Liraglutide
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Novo Nordisk · Phase 2 · Completed · Enrollment 706
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
- Placebo 2.4 mg (NNC0174-0833)
- Placebo 4.5 mg (NNC0174-0833)
- Placebo 1.2 mg (NNC0174-0833)
- Placebo 0.6 mg (NNC0174-0833)
- Placebo 0.3 mg (NNC0174-0833)
- Placebo 3.0 mg (Liraglutide)
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| NNC0174-0833, 4.5 mg | n/r | n/r | n/r | n/r |
| NNC0174-0833, 2.4 mg | n/r | n/r | n/r | n/r |
| NNC0174-0833, 1.2 mg | n/r | n/r | n/r | n/r |
| NNC0174-0833, 0.6 mg | n/r | n/r | n/r | n/r |
| NNC0174-0833 0.3 mg | n/r | n/r | n/r | n/r |
| Placebo 2.4 mg (NNC0174-0833) | 74.12% | 43.97% | n/r | n/r |
| Placebo 4.5 mg (NNC0174-0833) | 88.74% | 53.49% | n/r | n/r |
| Placebo 1.2 mg (NNC0174-0833) | 75.84% | 35.79% | n/r | n/r |
| Placebo 0.6 mg (NNC0174-0833) | 61.98% | 24.06% | n/r | n/r |
| Placebo 0.3 mg (NNC0174-0833) | 57.47% | 15.28% | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Placebo 3.0 mg (Liraglutide) | 76.16% | 39.43% | n/r | n/r |
Not shown
- NNC0174-0833, 4.5 mg: endpoint not reported
- NNC0174-0833, 2.4 mg: endpoint not reported
- NNC0174-0833, 1.2 mg: endpoint not reported
- NNC0174-0833, 0.6 mg: endpoint not reported
- NNC0174-0833 0.3 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported